[ad_1]
Welcome to this week’s Chutes & Ladders, our roundup of hires, layoffs and retirements across the industry. Please send your store’s good or bad word to Kyle LaHucik, and we’ll feature it here at the end of each week.
Johnson & Johnson chief scientist Stoffels to leave around the same time as CEO Gorsky
Johnson & johnson
Paul Stoffels, MD, will retire at the end of this year from his position as Scientific Director.
His nine-year stint in this role helped rejuvenate R&D and double pharmaceutical sales from 2009 to 2020 with the introduction of blockbuster drugs like Darzalex and Imbruvica. Stoffels also helped found J&J Innovation, which has incubated over 700 companies. His successor has not been named. Stoffels will be leaving around the same time as CEO Alex Gorsky. Fierce biotech
Ensoma takes over Nuwaysir, Chairman of Bayer’s BlueRock and Chairman of the Alliance for Regenerative Medicine, as CEO
Ensoma
Emile Nuwaysir, Ph.D., adds the CEO position to his resume just two months after losing the title.
He now serves as head of in vivo gene therapy biotechnology Ensoma after leading Bayer’s $ 1 billion bet on Parkinson’s disease in human tests earlier this summer. Nuwaysir is still president of BlueRock Therapeutics, the biotechnology behind this effort, and is also president of the Alliance for Regenerative Medicine. It is an organization that brings together more than 400 cell and gene therapy biopharmas. Fierce biotech
Novartis Biomedical Research Institutes Oncology Unit Debuts Genentech’s Malek For Cancer Research
Novartis
Shiva Malek, Ph.D., will lead cancer research at Novartis’ NIBR.
Malek is leaving Genentech from Roche, where she was vice president of discovery oncology for the past six months after working in cancer research at pharma for over 15 years. There, Malek helped create the Small Molecule Drug Discovery Team. At Novartis’ NIBR, Malek takes on the role of Global Head of Oncology at the Cambridge, Massachusetts “Innovation Engineâ€. The engine of innovation has stalled in recent months with the departure of executives Jeff Engelman, MD, Ph.D., Peter Hammerman, MD, Ph.D., and Gopi Shanker, Ph.D. Fierce biotech
> Marc Cohen and Malcolm salter left the board of directors of the Dana-Farber Cancer Institute after doing an about-face on the group’s position on allowing directors to invest in its startups. Fierce biotech
> Kojin Therapeutics completed its leadership team with the hiring of Luba green wood as CEO. Greenwood is a board member of several biotechnology companies and a Managing Partner of the Dana-Farber Cancer Institute. Exit
> Therese Heah, MD, is the new chief medical officer of Kriya Therapeutics and chairman of the new biotechnology ophthalmology unit. Heah is from AsclepiX Therapeutics, where she was CMO and Executive Vice President of Operations. Exit
> John Frisson, Ph.D., was appointed Chief Strategy Officer and Tong Ming Fu, MD, Ph.D., becomes Scientific Director of IGM Biosciences to help lead the new Infectious Diseases business unit. Shiver is from Sanofi Pasteur, where he was senior vice president of vaccine R&D; Fu also joined Sanofi Pasteur, where he was responsible for vaccine research for North America. IGM also named Mary beth harler, MD, as chairman to lead the new autoimmunity and inflammation unit. Harler was most recently SVP and Head of Immunology and Fibrosis Development at Bristol Myers Squibb. Exit
> ChemoCentryx’s newest Chief Medical Officer and Executive Vice President is Rita jain, MD, who is from Immunovant, where she was the Marketing Director. Exit
> Laura Johnson, Ph.D., is Scientific Director at Verismo Therapeutics after leading preclinical translational research in the Oncology Unit of GlaxoSmithKline. Exit
> David Langer, MD, becomes Chief Medical Officer of Longeviti Neuro Solutions after serving as President of the Neurosurgery Unit at Lenox Hill Hospital in New York. Exit
> Promotion of ReForm organic products Robert mahoney, Ph.D., Scientific Director and Senior Kevin kavanaugh to the CFO. Exit
> Blake Aftab, Ph.D., has been promoted to Scientific Director and Senior Vice President of Adicet Bio. Exit
> Poseida Therapeutics promoted Johanna mylet to the financial director; Devon shedlock, Ph.D., was elevated to Scientific Director of Cell Therapy; Kristin martin became its new head of personnel and administration; and Lisa Portale has been appointed to the position of Senior Vice President of Regulatory Affairs. Exit
> John choi will be Vice President of Regulatory Affairs at Ambys Medicines after having held the same position at Platelet BioGenesis. Exit
> Dymeka Harrison left the role of Vice President of Global Strategic Marketing at Abbott to become Chief Commercial Officer of Foundation Medicine. Exit
> Sciences 37 hired Élisa Cascade as product manager and promoted Chris Ceppi to the CTO. Cascade comes to us from ERT, where she was Executive Vice President of Electronic Clinical Outcome Assessments. Exit
> Husband Scheiffele will assume the role of Executive Vice President and President of Ipsen’s International Specialized Care Unit effective November 1. She is from Novartis, where she was Managing Director of Big Pharma’s oncology units in the UK and Ireland. Exit
> Mati Gill, formerly Head of Government Affairs at Teva Pharmaceuticals, will be CEO of AION Labs, a new innovation lab focused on artificial intelligence and therapeutic challenges. AstraZeneca, Merck, Pfizer and Teva launched the alliance. Exit
> Coya Therapeutics appointed Gene Mack its CFO after Mack had held the same position at OncoC4. Exit
> Caris Life Sciences hired Andreas Tsukada as SVP and President of Japanese Operations and Head of International. Tsukada was previously Managing Director and Representative Director of Japanese Operations at Guardant. Exit
> Gareth Walters, Ph.D., will be the first Regulatory Director at Synairgen after leading Global Regulatory Affairs at Chugai Pharmaceuticals. Exit
> Excision BioTherapeutics has named three key leaders: Sara Turken as Advocate General, Manish anand as Senior Vice President of Regulatory Affairs and Robert Gunning as controller and vice-president. Turken was Legal Manager at Rocket Pharmaceuticals; Anand joined AskBio from Bayer, where he held the same position; and Gunning was CFO at Advanced Accelerator Application, a subsidiary of Novartis. Exit
> Timothy Hunting was appointed Director of Culture and Corporate Affairs of Xilio Therapeutics after serving as Director of Corporate Affairs at Editas Medicine. Exit
> Quantori hired Steve labkoff, MD, as Global Head of Clinical Informatics and Healthcare after serving as Data Manager at the nonprofit Multiple Myeloma Research Foundation. Exit
> Therese Bak-Thomsen, Ph.D., was promoted to Director of Discovery Biologics at the Novo Nordisk Research Center in Seattle.
> Brendan Smith will be the CFO of CRISPR Therapeutics after holding the same position at Translate Bio, which was recently sold to Sanofi for $ 3.2 billion. Smith replaces Michael tomsicek, who is retiring at the end of the year. Exit
> Jason haas will serve as CFO of Syros Pharmaceuticals after being co-head of Healthcare Investment Banking for the Americas at Barclays. Exit
> MiNA Therapeutics named four new leaders: Roche’s Troels Koch as senior vice president of chemistry; GlaxoSmithKline’s Julia Vassiliadou as vice president of clinical operations; from Eisai Ilian Tchakov as vice president of clinical development; and Kevin Fettes as vice president of chemistry, manufacturing and controls. Exit
> Orlando baeza becomes Medable’s first Marketing Director after holding this position at Kajabi and Pollen. Exit
> Vedanta Biosciences hired Simona levi, Ph.D., as General Counsel and Corporate Secretary after serving as General Counsel at Cell Signaling Technology. Exit
[ad_2]